In multivariate analysis , the growth rate was 0.37 mm/year in eyes receiving bevacizumab and 0.49 mm/year in eyes receiving ranibizumab ( difference , 0.11 mm/yr ; 95 % confidence interval [ CI ] , 0.01-0 .22 ; P = 0.03 ) .